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Inherent recipient factors, including pretransplant
diagnosis, obesity and elevated pulmonary pressures,
are established primary graft dysfunction (PGD) risks.
We evaluated the relationship between preoperative
lung injury biomarkers and PGD to gain further
mechanistic insight in recipients. We performed a
prospective cohort study of recipients in the Lung
Transplant Outcomes Group enrolled between 2002
and 2010. Our primary outcome was Grade 3 PGD on
Day 2 or 3.Wemeasured preoperative plasma levels of
five biomarkers (CC-16, sRAGE, ICAM-1, IL-8 and
Protein C) that were previously associated with PGD
when measured at the postoperative time point. We
used multivariable logistic regression to adjust for
potential confounders. Of 714 subjects, 130 (18%)
developed PGD. Median CC-16 levels were elevated in
subjects with PGD (10.1 vs. 6.0, p<0.001). CC-16 was
associated with PGD in nonidiopathic pulmonary
fibrosis (non-IPF) subjects (OR for highest quartile of
CC-16: 2.87, 95% CI: 1.37, 6.00, p¼ 0.005) but not in
subjects with IPF (OR 1.38, 95% CI: 0.43, 4.45, p¼ 0.59).
After adjustment, preoperative CC-16 levels remained
associated with PGD (OR: 3.03, 95% CI: 1.26, 7.30,
p¼ 0.013) in non-IPF subjects. Our study suggests the
importance of preexisting airway epithelial injury in
PGD. Markers of airway epithelial injury may be helpful
in pretransplant risk stratification in specific recipients.
Keywords: Acute lung injury, biomarkers, CC-16, lung
transplantation, primary graft dysfunction
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Introduction
Primary graft dysfunction (PGD) is a form of acute lung
injury (ALI) occurring within 72 h of lung transplanta-
tion (1,2). It is the leading cause of early morbidity and
mortality after transplant (3,4), yet the mechanisms driving
the development of PGD remain unclear. Prior work
evaluating postoperative time points has identified plasma
biomarkers associated with concurrent PGD, including
soluble receptor for advanced glycation end products
(sRAGE), club (Clara) cell secretory protein (CC-16), Protein
C and intercellular adhesion molecule-1 (ICAM-1) (5–8).
These markers have helped establish potential mecha-
nisms occurring during clinical PGD, and have demonstrat-
ed discriminant validity as a quantitative measure of PGD
(9). However, there is a lack of knowledge of mechanisms
occurring prior to transplant in the recipient that may be
important in the development of PGD, and better preoper-
ative recipient risk stratification may allow for changes in
management or therapy prior to transplantation to reduce
the risk of PGD.
Recently, we and others have established several recipient-
related clinical risk factors for PGD, including obesity,
presence of pulmonary hypertension and predisposing
diagnosis (4). Identification of the biological processes
underlying these clinical PGD associations is important
because itwill give insight into potentiallymodifiable factors
prior to transplantation. For example, although predisposing
diagnosis is not modifiable prior to transplantation, en-
hanced understanding of what is driving the increased risk
of a particular diagnosis may provide targets for therapy to
decrease PGD risk prior to transplantation. Additionally,
studying biological markers within known risk groups is
important as there are likely several different mechanisms
contributing to the risk of PGD and measurement of
biomarkers may allow for individualized management
decisions to decrease PGD risk.
In order to further study potential mechanisms underlying
previously established clinical risk factors and identify
potential biological targets prior to transplantation to reduce
the risk of development of PGD, we tested the association
between five known PGD lung injury biomarkers measured
preoperatively in the recipient and the subsequent risk of
development of PGD.
Methods
Study population
The Lung Transplant Outcomes Group cohort is a multi-center, prospective
study that has been previously described (5,6). In prior studies, we have
measured postoperative biomarkers in smaller subsets of this cohort
study (6–8). In this study, we measured five preoperative biomarkers in a
large cohort of subjects that is expanded and distinct frompreviously studied
cohorts. We included subjects transplanted between July 2002 and
May 2010 with at least one biomarker measurement at the preoperative
time point. The majority of samples were collected immediately prior to
transplantation during the transplant admission; however, a fraction was
collected at the time of listing. Samples were processed within 60min and
then stored at 808C for subsequent analysis, and clinical data were
collected prospectively for all subjects as described previously (5,7,10).
Mortality information was collected from each center and supplemented
with data from United Network for Organ Sharing (11). Institutional Review
Board approval was obtained from each participating center. Informed
consent was obtained from each subject enrolled in the cohort.
Determination of PGD grade
Our primary outcome was Grade 3 PGD at 48 or 72 h after transplantation.
PGD grade was determined using the International Society for Heart and
Lung Transplantation consensus definition (2,10,12). Two blinded physicians
examined chest radiographs to assess for the presence of PGD. Radio-
graphs qualified for PGD if the transplanted lung(s) had diffuse infiltrates.
Radiographs and arterial blood gases were assessed at the time of
admission to the ICU after transplantation (T0), and 24, 48 and 72 h after
transplantation. The severity of PGDwas graded according to the PaO2/FiO2
ratio, with a PaO2/FiO2 ratio less than 200 defining Grade 3 PGD (13).
Measurement of sRAGE, ICAM-1, Protein C, IL-8 and CC-16
Biomarkers were chosen because of previously reported associations with
ALI or PGD (5,7,14,15). Protein C was measured using the Actichrome
Protein C assay (American Diagnostica, Greenwich, CT). The intra-assay
coefficient of variation was 5.5%. sRAGE, ICAM-1 and IL-8 were measured
by ELISA (R&D, Minneapolis, MN). The intra-assay coefficients of variation
were 7%, 5% and 3%, respectively. CC-16 levels were measured using a
commercially available ELISA (Biovender, Candler, NC). The intra-assay
coefficient of variation was 4%. All analytes were measured in duplicate.
Statistical analysis
Biomarkers were analyzed either continuously or using quartiles, based on
fractional polynomial fit plots evaluating the relationship between each
biomarker and predicted probabilities of PGD (16), as well as categorizing
each biomarker into quartiles as a dummy variable in logistic regression
models with PGD as the outcome. We evaluated CC-16 stratified by
diagnosis (idiopathic pulmonary fibrosis [IPF] vs. non-IPF) based on our
previous finding that diagnosis is an effect modifier of the relationship
between CC-16 and PGD (8,17). We performed a sensitivity analysis of the
association of biomarkers by time of collection, repeating the analyses in
those subjects who had plasma collected at the time of listing, defined as
greater than 24 h prior to transplantation.
We used multivariable logistic regression to evaluate the relationship
between each biomarker and PGD while evaluating for confounding using
variables previously demonstrated to be risk factors for PGD, including BMI,
mean pulmonary arterial pressure (mPAP), transplant type, ischemic time,
FiO2 at reperfusion, female sex and parity, pretransplant diagnosis, donor
smoking (defined as any history of smoking) and use of cardiopulmonary
bypass (18). Using a prediction model previously developed (19) for PGD
using bootstrap resampling methods, which incorporated pretransplant
diagnosis, obesity and pulmonary artery pressure, we evaluated significant
biomarkers for incremental predictive utility by comparing area under the
curve (AUC) for themodel with an individual biomarker to themodel without.
A likelihood ratio testwas used to evaluate for significant differences in AUC.
Multiple imputation was used to account for missing data in the
covariates (20). Imputation was not used in either the exposure (biomarker)
or the outcome (grade of PGD) variables; the very few individuals with
missing biomarker values were excluded from analyses. p-Values of less
than 0.05 were considered significant. Analyses were performed using
STATA version 12.0 (STATA Corp., College Station, TX).
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Results
There were 714 subjects in the study, of which 130 (18%,
95% CI: 15%, 21%) developed PGD. The majority of
plasma samples were obtained at the time of transplanta-
tion; however, there were 126 subjects (19%) who had
samples collectedmore than 24h prior to transplantation. In
those subjects, plasma samples were collected at the time
of listing. The average time between collection and
transplantation in those subjectswas 80 96 days.Missing
biomarker values (n¼2) were due to assay failure.
Subjects with PGD more frequently received a lung from a
smoking donor, were more obese and had IPF and PAH
more often as a pretransplant diagnosis (10). Additionally,
subjects with PGD had higher mPAP, more frequent red
blood cell transfusions and more frequent use of cardiopul-
monary bypass (Table 1). The percentage of missing data
for each covariate is listed in Table 1. There were no
significant differences in plasma levels of sRAGE, ICAM-1,
IL-8 and Protein C between those with PGD and those
without (Table 2).
Median plasma CC-16 levels were higher in subjects with
PGD compared to those without (10.1 [IQR: 5.2, 19] vs. 6.0
[IQR: 3.4, 12.8], p< 0.001). We analyzed CC-16 categori-
cally, in quartiles, based on the relationship of CC-16 with
predicted probability of PGD generated from the fractional
polynomial fit plot (Figure 1). There was an increased odds
of PGD in subjects in the third quartile of CC-16 (OR: 1.89,
95%CI: 1.08, 3.32, p¼ 0.03) and the highest quartile of CC-
16 (OR: 2.35, 95% CI: 1.35, 4.08, p¼ 0.002) compared to
the lowest quartile of CC-16. When we evaluated CC-16
and pretransplant diagnosis (stratified as IPF vs. non-IPF),
we found that the highest quartile of CC-16 had more
subjects with IPF compared to other diagnoses (118 vs. 60,
p< 0.001). There was no detectable association between
CC-16 and PGD in subjects with IPF (OR for highest quartile
of CC-16 1.38, 95% CI: 0.43, 4.45, p¼ 0.59). Plasma CC-16
levels were higher in subjects with PGD than without in the
sub-group of non-IPF subjects (Figure 2A and B). The
association between CC-16 and PGD was unchanged in
subjects without IPF (OR for third quartile: 1.90 95% CI:
0.97, 3.72, p¼ 0.06 and highest quartile OR 2.87, 95% CI:
1.37, 6.01, p¼ 0.005). In a multivariable model with
previously identified risk factors for PGD, the association
between CC-16 and PGD in non-IPF subjects remained (OR
for third quartile: 2.16, 95%CI: 1.00, 4.63, p¼ 0.049 and for
fourth quartile: 3.03, 95%CI: 1.26, 7.30, p¼ 0.013; Table 3).
Given the association between preoperative plasma CC-16
and PGD, we evaluated CC-16 as a possible predictor for
PGD in non-IPF subjects. First, we evaluated the predictive
utility of CC-16 alone, which had an AUC of 0.60. Then,
based on a previous study (19), we analyzed the predictive
utility of pretransplant diagnosis, BMI category and mPAP
as a basemodel. The negative predictive value of thismodel
was 93%, and the positive predictive value was 20%. With
the addition of CC-16 to the model, there were no
significant improvements in the negative or positive
predictive values (90% and 15%, respectively), despite
statistically significant improvement in the AUC (0.72 for
modelwith CC-16 vs. 0.70 for base clinicalmodel, p¼ 0.04).
Therefore, although elevated preoperative plasma CC-16 is
an independent risk factor and possible biomarker of PGD, it
may not be clinically useful in prediction of PGD when
added to known clinical predictor variables.
In sensitivity analyses, the relationship between the
biomarkers and the PGD did not change significantly by
time of sample collection. In subjects who had samples
collected at the time of transplantation, the relationship
between CC-16 and PGD was unchanged (OR for highest
quartile of CC-16: 2.07, 95% CI: 1.00, 4.31, p¼ 0.05). In
subjects who had samples collected greater than 24 h from
the time of transplantation (n¼174), there was no change
in the relationship between CC-16 and PGD (OR for the
highest quartile of CC-16 was 3.8, 95% CI: 1.19, 12.14,
p¼ 0.02). There were not enough subjects to perform a
stratified analysis by individual diagnosis category.
Discussion
In this study, we have demonstrated an association
between plasma CC-16 levels measured preoperatively
and PGD. This association was the strongest in subjects
without IPF as a pretransplant diagnosis, and in subjects in
the highest quartile of plasma CC-16. The association was
independent of adjustment frommultiple known confound-
ing variables, indicating that the level of epithelial injury, as
represented by circulating CC-16 levels, may predispose to
PGD prior to the transplant procedure. Although CC-16 was
not a good predictor of PGD, we have demonstrated the
utility of CC-16 as a preoperativemarker of PGD. This study
builds on our prior work evaluating biomarkers in
PGD (5,6,8) by exclusively evaluating the preoperative
time point in a large cohort of prospectively studied
transplant recipients, with adequate power to evaluate
the role of biomarkers in prespecified sub-groups.
CC-16 is secreted by epithelial cells in the distal respiratory
tract and acts to protect the integrity of the epithelial lining
against inflammation and oxidant stress (21). In sarcoidosis,
CC-16 is a biomarker of parenchymal disease severity, with
increased levels being reflective of increasing parenchymal
disease (15,22). CC-16 has also been evaluated as a
biomarker of ALI, and plasma levelsmeasured at the time of
injury are decreased compared to other causes of pulmo-
nary edema (23,24). In our study, increased plasma levels of
CC-16 in the recipient prior to transplantation are associated
with subsequent PGD. The difference in directionality from
ALI may be because our measurement was taken prior to
the development of lung injury, not during, indicating that
preexisting epithelial injury is associated with subsequent
graft dysfunction. It is possible that systemic up-regulation
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of lung epithelial injury pathways prior to transplantation
leads to an increased susceptibility of PGD. Future
investigation on the systemic immune effectors of these
pathways in the posttransplant period is important.
We found that the associationwas the strongest in subjects
without IPF as a pretransplant diagnosis. Overall, subjects
with IPF had a significantly higher CC-16 level compared to
other pretransplant diagnoses. The lack of association
between CC-16 and PGD in IPF subjects may be that
subjects with IPF already had such a strong signal of
epithelial injury prior to transplantation that any subsequent
injury related to PGD is difficult to detect as levels in IPF
patients are so high (25). Alternatively, a recent study
demonstrated that chronic obstructive pulmonary disease
(COPD) patientswith high levels of circulating inflammatory
markers in a symptom-free period had a greater number of
exacerbations (26). It may be that patients with COPD and
other non-IPF diagnoses with high CC-16 levels are a sub-
group of ‘‘exacerbators’’ that are at increased risk for
Table 1: Univariate analysis of donor, recipient in perioperative variables stratified by primary graft dysfunction (PGD) status
Covariate Number imputed, n (%) PGD (n¼130) Non-PGD (n¼584) p-Value
Donor variables
Male gender, n (%) 2 (0.3) 71 (55) 341 (58) 0.43
Age 7 (1) 35.414.8 34.814.1 0.70
Mode of death, n (%) 1 (<1) 0.87
Trauma 49 (38) 238 (41)
Stroke 56 (43) 235 (40)
Anoxia 9 (7) 46 (8)
Other 16 (12) 65 (11)
Race, n (%) 9 (1) 0.66
Caucasian 87 (67) 365 (63)
African American 26 (20) 117 (20)
Other 17 (13) 102 (17)
Any smoking, yes 27 (4) 70 (54) 246 (43) 0.001
Recipient variables
Male gender, n (%) 3 (<1) 73 (56) 311 (53) 0.55
Age 6 (1) 52.112.7 53.012.8 0.47
BMI 14 (2) 26.04.7 24.64.5 0.002
BMI category, n (%) 0.008
<18.5 11 (8) 59 (10)
18.5–25 40 (31) 258 (44)
25–30 52 (40) 196 (34)
>30 27 (21) 71 (12)
Pulmonary diagnosis, n (%) 3 (<1) <0.001
Chronic obstructive pulmonary disease 33 (26) 256 (44)
Idiopathic pulmonary fibrosis 56 (43) 180 (31)
Cystic fibrosis 13 (10) 96 (16)
Sarcoidosis (3) 3 (2) 15 (3)
Pulmonary arterial hypertension (4) 13 (10) 15 (3)
Other 12 (9) 22 (4)
mPAP 136 (19) 35.017.6 27.910.2 <0.001
mPAP severity category, n (%) <0.001
<25mm Hg (normal) 41 (32) 253 (43)
25–40mm Hg (mild) 45 (35) 271 (46)
41–55mm Hg (moderate) 33 (25) 51 (9)
>55mm Hg (severe) 11 (8) 9 (2)
Race, n (%) 3 (<1) 0.018
Caucasian 103 (79) 506 (87)
African American 21 (16) 44 (8)
Other 6 (5) 34 (6)
Operative variables
Ischemic time, min 22 (3) 32992.2 30592.3 0.008
Transplant type, single, n (%) 4 (1) 39 (30) 190 (33) 0.58
PRBC >1L, n (%) 0 (0) 46 (35) 124 (21) 0.002
Cardiopulmonary bypass use, n (%) 4 (1) 78 (60) 196 (34) <0.001
PGD is defined as Grade 3 PGD on Day 2 or 3 after lung transplantation. Continuous variables are listed as mean standard deviation.
Percentages may not exactly equal 100% because of rounding.
mPAP, mean pulmonary arterial pressure; PRBC, packed red blood cells.
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epithelial injury after transplant, and that relationship is
washed out in IPF where there are consistently high CC-16
levels in all patients.
When added to a predictive model using clinical covariates,
CC-16 only had a slight increase in utility for predicting PGD.
Our findings indicate that preoperative CC-16 levels are
independently associated with PGD, and worthy of further
study into the mechanism of development of PGD in those
subjects without IPF, although it has not been proven a
useful predictor of those who will go on to develop PGD
when measured preoperatively.
We were unable to demonstrate an association between
Protein C, ICAM-1, lL-8 and sRAGE at the preoperative time
point and PGD. Protein C, ICAM-1 and sRAGE have
established associations with PGD at postoperative time
point (5,7) and IL-8 is a marker of ALI (27); IL-8 was recently
demonstrated to have good predictive utility for ALI when
measured in the emergency department. Our inability to
detect an association between these biomarkers and the
subsequent development of PGD may be because these
Table 2: Median (interquartile range) preoperative biomarker levels by PGD status
Biomarker n PGD (n¼130) Non-PGD (n¼584) p-Value
CC-16 (ng/mL) 712 10.1 (5.2, 19.0) 6.0 (3.4, 12.8) <0.001
sRAGE (pg/mL) 712 743.3 (438.9, 2030.8) 725.6 (391.7, 1462.6) 0.27
ICAM-1 (ng/mL) 714 223 (135, 333) 214 (137, 340) 0.97
IL-8 (pg/mL) 714 5.5 (3.3, 12.9) 5.3 (3, 10) 0.36
Protein C (% control) 713 110 (77, 140) 105 (79, 134) 0.44
CC-16, club (Clara) cell secretory protein; ICAM-1, intercellular adhesion molecule-1; PGD, primary graft dysfunction; sRAGE, soluble
receptor for advanced glycation end product.
p-Valueswere calculated using theWilcoxon-rank sum test. The number of subjectswith a valid biomarkermeasurement is listed next to the
biomarker.
Figure 1: Relationship of CC-16 level to predicted probability
of Grade 3 PGD on Day 2 or 3 using fractional polynomial plot.
The gray area describes the 95% confidence interval. CC-16, club
(Clara) cell secretory protein; PGD, primary graft dysfunction.
Figure 2: (A) CC-16 levels in those with PGD and those without
PGD in subjects without idiopathic pulmonary fibrosis (IPF) as a
pretransplant diagnosis. (B) CC-16 levels in those with PGD and
those without PGD in subjects with IPF as a pretransplant
diagnosis. The horizontal line in the middle of each box indicates
the median; the top and bottom borders mark the 75th and 25th
percentiles, respectively; and the whiskers mark the 90th and 10th
percentiles. CC-16, club (Clara) cell secretory protein; PGD, primary
graft dysfunction.
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biomarkers reflect mechanisms that are activated by the
process of ischemia-reperfusion injury, and not mecha-
nisms that are active in the recipient prior to transplantation.
Additionally, a small proportion of our preoperative bio-
markers was measured at months prior to transplantation,
and may have diluted our ability to detect an association
using these biomarkers.
Our study has several limitations. First, not all of the plasma
measurementswere taken at the same time point, so there
may have been other confounding factors associated with
the earlier measurements. However, in sensitivity analy-
ses, the association between CC-16 and PGD was
unchanged in subjects who had plasma measurements at
the time of listing or at the time of transplantation. This
increases applicability of our findings, as the association
was still present with biomarkers measured early; it
supports the hypothesis that there may be time for
potential interventions prior to transplantation. Second,
we do not have available data on concomitant immuno-
suppressant medications at the time of preoperative
blood draws. Although prior studies have successfully
measured these markers in the setting of concomitant
steroid use, little is known about the effect of immuno-
suppressants on human plasma levels; thus, residual
confounding may account for some of our negative
results (23,28–30). Third, we used multiple imputation to
account for missing data in the covariates; however,
missing data on clinical covariates were rare and we had
no missing PGD grade and minimal missing biomarker
measurements within the cohort.
In conclusion, we have demonstrated an association
between preoperative levels of CC-16 and PGD in subjects
without IPF as a pretransplant diagnosis. This finding sheds
light on pretransplant, potentially modifiable factors that
may lead to PGD. Further research iswarranted focusing on
the mechanisms of how recipient epithelial injury ‘‘primes’’
the lung for subsequent PGD.
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